The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study-Reference-Cited by-同舟云学术

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Published:2015-01 Issue:1 Volume:16 Page:25-35
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Finn Richard S,Crown John P,Lang Istvan,Boer Katalin,Bondarenko Igor M,Kulyk Sergey O,Ettl Johannes,Patel Ravindranath,Pinter Tamas,Schmidt Marcus,Shparyk Yaroslav,Thummala Anu R,Voytko Nataliya L,Fowst Camilla,Huang Xin,Kim Sindy T,Randolph Sophia,Slamon Dennis J

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Molecular portraits of human breast tumours;Perou;Nature,2000

2. Global cancer statistics;Jemal;CA Cancer J Clin,2011

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

4. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer;Baselga;N Engl J Med,2012

5. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

Cited by 1578 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation;Cancer Treatment Reviews;2024-11

2. The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review;Critical Reviews in Oncology/Hematology;2024-10

3. Dose reduction and discontinuation due to the combination of CDK4/6 inhibitors and endocrine drugs: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-09-13

4. Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer;Current Oncology;2024-09-12

5. Efficacy and Safety of Abemaciclib in Combination With Endocrine Therapy for HR+/HER2− Advanced or Metastatic Breast Cancer;American Journal of Clinical Oncology;2024-09-09